Zai Lab Stock Price, News & Analysis (NASDAQ:ZLAB)

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zai Lab in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ZLAB shares.
View ZLAB analyst ratings or view top-rated stocks.

4 brokers have issued 12-month target prices for Zai Lab's stock. Their ZLAB share price targets range from $62.50 to $128.00. On average, they expect the company's share price to reach $79.97 in the next year. This suggests a possible upside of 190.8% from the stock's current price.
View analysts price targets for ZLAB or view top-rated stocks among Wall Street analysts.

Zai Lab's stock was trading at $30.70 at the start of the year. Since then, ZLAB shares have decreased by 10.4% and is now trading at $27.50.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 6th 2024.
View our ZLAB earnings forecast.

Zai Lab Limited (NASDAQ:ZLAB) announced its earnings results on Tuesday, November, 7th. The company reported ($0.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.94) by $0.23. The business earned $69.23 million during the quarter, compared to analysts' expectations of $67.12 million. Zai Lab had a negative net margin of 114.22% and a negative trailing twelve-month return on equity of 31.19%.

ETFs with the largest weight of Zai Lab (NASDAQ:ZLAB) stock in their portfolio include Global X China Biotech Innovation ETF (CHB), ETFMG Treatments Testing and Advancements ETF (GERM), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Products ETF (BBP), Loncar China Biopharma ETF (CHNA), Fidelity Disruptive Medicine ETF (FMED) and Invesco Golden Dragon China ETF (PGJ) and

Based on aggregate information from My MarketBeat watchlists, some companies that other Zai Lab investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Inseego (INSG), Niu Technologies (NIU), JD.com (JD), Bilibili (BILI), Marvell Technology (MRVL), Baidu (BIDU), BioXcel Therapeutics (BTAI) and Baozun (BZUN).

(ZLAB) raised $100 million in an IPO on Wednesday, September 20th 2017. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Citigroup and Leerink Partners served as the underwriters for the IPO.

Zai Lab's stock is owned by many different retail and institutional investors. Top institutional shareholders include Invesco Ltd. (3.25%), Wellington Management Group LLP (1.95%), Segantii Capital Management Ltd (1.81%), Bamco Inc. NY (1.60%), FMR LLC (1.28%) and Rock Springs Capital Management LP (1.25%). Insiders that own company stock include Frazor Titus Edmondson III, Harald Reinhart, John D Diekman, John D Diekman, Joshua L Smiley, Kai-Xian Chen, Peter Wirth, Tao Fu, William Ki Chul Cho, William Lis, Yajing Chen and Ying Du.
View institutional ownership trends.

Shares of ZLAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.